Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease

dc.contributor.authorSubramaniam, Kavitha
dc.contributor.authorFallon, Kieran
dc.contributor.authorRuut, Tom
dc.contributor.authorLane, D
dc.contributor.authorMcKay, R.
dc.contributor.authorShadbolt, Bruce
dc.contributor.authorAng, S.
dc.contributor.authorCook, Matthew
dc.contributor.authorPlatten, J.
dc.contributor.authorPavli, Paul
dc.contributor.authorTaupin, Douglas
dc.date.accessioned2019-07-25T01:52:10Z
dc.date.issued2015
dc.date.updated2019-03-31T07:21:46Z
dc.description.abstractBackground Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF-κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim As TNF is a potent activator of NF-κB, and anti-TNF agent infliximab (IFX) prevents NF-κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods We performed a prospective, repeated-measures cohort study in adult Crohn's disease patients with an acute disease flare. Patients were instructed not to vary diet or activity. Concomitant medications were kept stable. At week 1 (pre-treatment), week 16 (post-IFX induction) and week 25 (post-first IFX maintenance dose), we assessed (i) MRI volume of quadriceps femoris at anatomical mid-thigh; (ii) maximal concentric quadriceps contractions strength at three specific speeds of contraction; (iii) physical activity by validated instrument (IPAQ); (iv) Three-day food record of intake and composition (food-weighing method); (v) Serum levels of IL6. Results Nineteen patients (58% female; mean age 33.2 ± 10.7 years) were recruited. IFX increased muscle volume in both legs from baseline (right, 1505 cm3) to week 25 (right, 1569 cm3; P = 0.010). IFX also increased muscle strength in both legs from baseline (right 30°/s, 184.8 Nm) to week 25 (right 30°/s, 213.6 Nm; P = 0.002). Muscle volume gain correlated with male gender (P = 0.003). Significant gains in muscle volume and strength were unrelated to prednisolone use. Serum IL6 levels decreased by week 25 (P = 0.037). Conclusion The anti-TNF agent infliximab reverses inflammatory sarcopenia in patients with Crohn's disease.en_AU
dc.description.sponsorshipThe project was funded entirely by the Canberra Hospital Private Practice Trust Fund.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0269-2813en_AU
dc.identifier.urihttp://hdl.handle.net/1885/164703
dc.language.isoen_AUen_AU
dc.publisherWiley-Blackwellen_AU
dc.rights© 2015 John Wiley & Sons Ltden_AU
dc.sourceAlimentary pharmacology & therapeuticsen_AU
dc.subjectC reactive proteinen_AU
dc.subjectimmunomodulating agenten_AU
dc.subjectinfliximaben_AU
dc.subjectinterleukin 6en_AU
dc.subjectmesalazineen_AU
dc.subjectprednisoloneen_AU
dc.subjectautacoiden_AU
dc.subjectimmunoglobulin enhancer binding proteinen_AU
dc.subjectinfliximaben_AU
dc.subjectmonoclonal antibodyen_AU
dc.subjecttumor necrosis factor alphaen_AU
dc.subjectacute diseaseen_AU
dc.subjectadulten_AU
dc.subjectageden_AU
dc.subjectArticleen_AU
dc.subjectcaloricen_AU
dc.titleInfliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's diseaseen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue5en_AU
local.bibliographicCitation.lastpage428en_AU
local.bibliographicCitation.startpage419en_AU
local.contributor.affiliationSubramaniam, Kavitha, College of Health and Medicine, ANUen_AU
local.contributor.affiliationFallon, Kieran, College of Health and Medicine, ANUen_AU
local.contributor.affiliationRuut, Tom, College of Health and Medicine, ANUen_AU
local.contributor.affiliationLane, D, Department of Imagingen_AU
local.contributor.affiliationMcKay, R., Department of Imagingen_AU
local.contributor.affiliationShadbolt, Bruce, College of Health and Medicine, ANUen_AU
local.contributor.affiliationAng, S., Cancer Researchen_AU
local.contributor.affiliationCook, Matthew, College of Health and Medicine, ANUen_AU
local.contributor.affiliationPlatten, J., Gastroenterology and Hepatology Uniten_AU
local.contributor.affiliationPavli, Paul, College of Health and Medicine, ANUen_AU
local.contributor.affiliationTaupin, Douglas, College of Health and Medicine, ANUen_AU
local.contributor.authoremailu1814247@anu.edu.auen_AU
local.contributor.authoruidSubramaniam, Kavitha, u5430653en_AU
local.contributor.authoruidFallon, Kieran, u4140859en_AU
local.contributor.authoruidRuut, Tom, u4234516en_AU
local.contributor.authoruidShadbolt, Bruce, u1814247en_AU
local.contributor.authoruidCook, Matthew, u2572788en_AU
local.contributor.authoruidPavli, Paul, u3683784en_AU
local.contributor.authoruidTaupin, Douglas, u3510029en_AU
local.description.embargo2037-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor110307 - Gastroenterology and Hepatologyen_AU
local.identifier.ariespublicationu4425841xPUB83en_AU
local.identifier.citationvolume41en_AU
local.identifier.doi10.1111/apt.13058en_AU
local.identifier.scopusID2-s2.0-84921917087
local.identifier.thomsonID000348731400002
local.identifier.uidSubmittedByu4425841en_AU
local.publisher.urlhttps://www.wiley.com/en-gben_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
01_Subramaniam_Infliximab_reverses_2015.pdf
Size:
482.77 KB
Format:
Adobe Portable Document Format
Back to topicon-arrow-up-solid
 
APRU
IARU
 
edX
Group of Eight Member

Acknowledgement of Country

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.


Contact ANUCopyrightDisclaimerPrivacyFreedom of Information

+61 2 6125 5111 The Australian National University, Canberra

TEQSA Provider ID: PRV12002 (Australian University) CRICOS Provider Code: 00120C ABN: 52 234 063 906